Schäfer et al., Geringe körperliche Aktivität bei Patienten aus der SHCS
Geringe körperliche Aktivität bei Patienten aus der Schweizerischen HIV-Kohortenstudie. AIDS Care Sport ist gesund, so lautet der Volksmund. Tatsächlich konnte bei HIV-negativen Personen gezeigt werden, dass eine regelmässige körperliche Aktivität die Sterblichkeit erniedrigt, insbesondere aufgrund eines geringeren Risikos für Herzkreislauferkrankungen. Forscher aus der Schweizerischen HIV-Kohortenstudie haben nun untersucht, ob sich die körperliche Aktivität […]
Sculier et al., Rilpivirine use in the Swiss HIV Cohort Study
Rilpivirine use in the Swiss HIV Cohort Study: a prospective cohort study. BMC Infectious Diseases Sculier et al. aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study (SHCS) and to assess its effectiveness and safety over a 24 months period. All individuals […]
Béguelin et al., HCV treatment uptake, efficacy and impact on liver fibrosis in the SHCS
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver International Béguelin et al. aimed to assess the impact of new hepatitis C virus (HCV) direct acting agents (DAAs) on treatment uptake and efficacy as well as its repercussion on liver disease burden in the Swiss HIV […]
Blaser et al., Impact of screening and ART on anal cancer incidence
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. AIDS Blaser et al. aimed to model the impact of screening strategies and combination antiretroviral therapy (cART) coverage on anal cancer incidence in Switzerland. The authors developed an individual-based mathematical simulation model to predict anal cancer incidence in HIV-positive men-who-have-sex-with-men […]
O’Connor et al., Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. Lancet HIV O’Connor et al. for the INSIGHT START study group aimed to quantify the effects of immediate versus […]
Güler et al., L’espérance de vie des patients atteints du VIH
L’espérance de vie des patients atteints du VIH comparée à la population générale. AIDS Il est important de savoir si actuellement les patients atteints du VIH ont la même espérance de vie que les patients qui ne sont pas infectés. Ceci intéresse non seulement les patients mais aussi la surveillance de l’épidémie VIH et […]
Elzi et al., Adverse events of raltegravir and dolutegravir
Adverse events of raltegravir and dolutegravir. AIDS Elzi et al. aimed to compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. From 1 April 2006 to 31 December 2015, 4’041 HIV-infected individuals participating in the SHCS started an antiretroviral regimen containing either raltegravir (n=2’091) or dolutegravir (n=1’950). Of […]
Güler et al., La speranza di vita dei pazienti con infezione HIV
La speranza di vita dei pazienti con infezione HIV paragonata a quella della popolazione generale. AIDS È importante sapere se attualmente i pazienti con infezione da HIV hanno la stessa speranza di vita rispetto ai pazienti che non hanno l’infezione. Questo aspetto interessa non solamente i pazienti, ma è anche un dato rilevante nella […]
Güler et al., Lebenserwartung HIV-positiver Menschen
Lebenserwartung HIV-positiver Menschen im Vergleich zur Allgemeinbevölkerung. AIDS Die Frage, ob HIV-positive Menschen heutzutage dieselbe Lebenserwartung aufweisen wie HIV-negative Personen, ist für die Betroffenen zentral und zudem wichtig für die Überwachung der HIV-Epidemie und Planung von staatlichen Gesundheitsprogrammen. Die erfreuliche Antwort vorab: die Lebenserwartung von HIV-positiven Personen nähert sich immer mehr derjenigen der HIV-negativen […]
Kamal et al., HIV adherence and HAND
The presence of human immunodeficiency virus-associated neurocognitive disorders is associated with a lower adherence to combined antiretroviral treatment. Open Forum Infectious Diseases Kamal et al. investigated whether there is an association between a HIV-associated neurocognitive disorders (HAND) diagnosis and medication adherence. All patients included had a state-of-the-art neurocognitive assessment performed between January 2011 […]